Loxo Oncology, Inc. (NASDAQ:LOXO) Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. Following the transaction, the director now directly owns 144,118 shares of the company’s stock, valued at $12,970,620. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) opened at 85.03 on Friday. The stock has a 50 day moving average price of $86.39 and a 200 day moving average price of $68.85. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $95.92. The firm’s market cap is $2.54 billion.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same period last year, the company posted ($0.77) earnings per share. On average, equities analysts expect that Loxo Oncology, Inc. will post ($4.49) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/20/avi-z-naider-sells-5000-shares-of-loxo-oncology-inc-loxo-stock-2.html.

A number of institutional investors have recently made changes to their positions in the stock. FMR LLC grew its holdings in Loxo Oncology by 12.1% during the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after buying an additional 472,814 shares in the last quarter. BlackRock Inc. grew its holdings in Loxo Oncology by 20.6% during the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Loxo Oncology by 50.2% during the second quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares in the last quarter. Vanguard Group Inc. grew its holdings in Loxo Oncology by 24.7% during the second quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock worth $73,351,000 after buying an additional 181,471 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in Loxo Oncology by 372.0% during the second quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock worth $59,304,000 after buying an additional 582,862 shares in the last quarter.

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $94.00 price target (up from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Ifs Securities reaffirmed an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $102.00 price target (up from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $76.31.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.